Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead Sciences

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

Investors Business Daily

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

The Saturday Spread: These 3 Stocks Statistically May Be Cooking Up Something Special (GILD, WMB, XPEV)

Forget interpreting financial data and news items. If you want real edge, you’ve got to consider the metrics the market isn’t paying attention to.

Barchart

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV prevention.

Investors Business Daily

How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7.

Benzinga

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

The IBD SmartSelect Composite Rating for Gilead Sciences increased from 92 to a near-best 96 Monday.

Investors Business Daily

Gilead Sciences Earns Membership In 95-Plus Composite Rating Club

Gilead Sciences saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before.

Investors Business Daily

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.

Barchart

The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

Barchart

Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care

Gilead Sciences shares rose Friday after the Supreme Court tossed out a challenge that would have impacted HIV PrEP drugs.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work? And will biotech stocks take a hit?

The Conversation

US approves twice-yearly injection for HIV prevention – what you need to know about lenacapavir

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.

International Business Times UK

Marjorie Taylor Greene Buys Stocks Focusing on Tech, Energy, and a Biotech Firm That Recently Received FDA Approval for HIV Drug

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

International Business Times

US Approves Gilead's Twice-yearly Injection To Prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

Barchart

Is Gilead Sciences Stock Outperforming the S&P 500?

While Gilead Sciences has outperformed the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Evening Standard

Alzheimer's and cold sores: Are they linked?

Could cold sores be linked to an increased risk of developing dementia? Could cold sore treatment be used to treat Alzheimer’s?

Barchart

Unusual Options Alert: The Smart Money is Piling Into Gilead Sciences (GILD)

While the new political paradigm might not be the most conducive environment for Gilead Sciences, positive sentiment is brewing for GILD stock.

Investors Business Daily

Stocks Flashing Renewed Technical Strength: Gilead Sciences

A Relative Strength Rating upgrade for Gilead Sciences shows improving technical performance.

Investors Business Daily

Gilead Sciences Clears Technical Benchmark, Hitting 90-Plus RS Rating

Gilead Sciences sees its Relative Strength Rating hit the elite 90-plus level.

MarketBeat

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

345 stories

Amgen

343 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.